10x Genomics shared that PharosAI, a UK research group, will use its Xenium spatial platform. They aim to build a major multimodal cancer dataset. This dataset merges large-scale spatial biology data with advanced AI models. The goal is to speed up cancer research and improve care. PharosAI joins King’s College London and Queen Mary University of London with two NHS trusts. These are Guy’s and St Thomas’ and Barts Health. The UK Government’s Research Ventures Catalyst gave £18.9 million for this work. Support also comes from charities and industry partners. This team will turn old NHS cancer samples into high-resolution, AI-ready datasets. The initiative focuses on earlier diagnosis, precise therapies, and quicker treatment discoveries. It begins with breast cancer and will later include lung and pancreatic cancers.
10x Genomics and PharosAI Collaborate to Advance Cancer Research
“PharosAI changes that – creating rich, multimodal datasets and pairing them with cutting-edge AI models and analytical tools, powered by 10x Genomics’ advanced spatial technologies to enable earlier diagnoses, more targeted therapies and better outcomes for patients. By uniting universities, NHS Trusts, charities and industry, we are building an ecosystem for breakthrough discoveries,” said Professor Anita Grigoriadis, CEO of PharosAI. “Turning biological insight into impact requires scaled generation of consistent, high-quality data,” said Serge Saxonov, Chief Executive Officer and Co-founder of 10x Genomics. “With Xenium, PharosAI can convert decades of archived NHS cancer samples into robust, high-quality, spatially resolved datasets. This foundation is what makes it possible to move earlier, more precisely and with greater confidence toward the next generation of breakthroughs in cancer research.”